Oncolytics Biotech Inc. (ONCY) Q2 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to Oncolytics Biotech's second quarter 2023 conference call. All participants are now in a listen-only mode. There will be a question and answer session at the end of this call. Please be advised that this call is being recorded at the company's request. And I would like to turn the call over to John Patton, Director of Investor Relations and Communications. Please go ahead. Thank you, Operator, and good morning, everyone. Earlier this morning, Onclytics issued a press release providing recent operational highlights and financial results for the second quarter of 2023. A replay of today's call will be available on the events and presentation section of the Onclytics website approximately two hours after its completion. After remarks from company management, we will open the call for Q&A. As a reminder, various remarks made during this call contain certain forward-looking statements relating to the company's business prospects, and the development and commercialization of Pella ReRap, including statements regarding the company's focus, strategy and objectives, the company's belief as to the potential and mode of action of Pella ReRap as a cancer therapeutic, the company's plans regarding precision promise and the anticipated timing of entering into a definitive agreement in connection therewith, the company's plans and expectations regarding potential registrational studies, the company's business development plans and strategies, and other statements related to anticipated developments in the company's business. These statements are based on management's current expectations and beliefs and are subject to a number of factors which involve known and unknown risks, delays, uncertainties, and other factors not under the company's control that ma...